According to Bide Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price increase exceeded 30% for two consecutive trading days on August 7 and August 10, 2026, which is an abnormal fluctuation. After self-inspection and consultation with the controlling shareholders and actual controllers, as of the announcement date, the company and related parties had no important matters that should have been disclosed. Currently, production and operation are normal. No media reports, market rumors or hot conceptual matters have been discovered that have had a significant impact on the stock price. The relevant personnel did not trade the company's stock during this period. Remind investors to be aware of risks and invest rationally.

According to Bide Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price increase exceeded 30% for two consecutive trading days on August 7 and August 10, 2026, which is an abnormal fluctuation. After self-inspection and consultation with the controlling shareholders and actual controllers, as of the announcement date, the company and related parties had no important matters that should have been disclosed. Currently, production and operation are normal. No media reports, market rumors or hot conceptual matters have been discovered that have had a significant impact on the stock price. The relevant personnel did not trade the company's stock during this period. Remind investors to be aware of risks and invest rationally.